Evidence map›Paper›PMID 34430345›Full record

ArticleTranslational lung cancer research2021

Mitogen signal-associated pathways, energy metabolism regulation, and mediation of tumor immunogenicity play essential roles in the cellular response of malignant pleural mesotheliomas to platinum-based treatment: a retrospective study.

Alexander Mathilakathu, Sabrina Borchert, Michael Wessolly, Elena Mairinger, Hendrik Beckert, Julia Steinborn, Thomas Hager, Daniel C Christoph, Jens Kollmeier, Jeremias Wohlschlaeger and 5 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Alexander MathilakathuInstitute of Pathology, University Hospital Essen, University of Duisburg Essen, Essen, Germany.
Sabrina BorchertInstitute of Pathology, University Hospital Essen, University of Duisburg Essen, Essen, Germany.
Michael WessollyInstitute of Pathology, University Hospital Essen, University of Duisburg Essen, Essen, Germany.
Elena MairingerInstitute of Pathology, University Hospital Essen, University of Duisburg Essen, Essen, Germany.
Hendrik BeckertDepartment of Pulmonary Medicine, University Hospital Essen-Ruhrlandklinik, Essen, Germany.
Julia SteinbornInstitute of Pathology, University Hospital Essen, University of Duisburg Essen, Essen, Germany.
Thomas HagerInstitute of Pathology, University Hospital Essen, University of Duisburg Essen, Essen, Germany.
Daniel C ChristophDepartment of Medical Oncology, Evang. Kliniken Essen-Mitte, Essen, Germany.
Jens KollmeierDepartment of Pneumology, Helios Klinikum Emil von Behring, Berlin, Germany.
Jeremias WohlschlaegerInstitute of Pathology, University Hospital Essen, University of Duisburg Essen, Essen, Germany.
Thomas MairingerDepartment of Tissue Diagnostics, Helios Klinikum Emil von Behring, Berlin, Germany.
Kurt Werner SchmidInstitute of Pathology, University Hospital Essen, University of Duisburg Essen, Essen, Germany.
Robert F H WalterInstitute of Pathology, University Hospital Essen, University of Duisburg Essen, Essen, Germany.
Luka BrcicDiagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria.
Fabian D MairingerInstitute of Pathology, University Hospital Essen, University of Duisburg Essen, Essen, Germany.
University of Duisburg-Essen · DEHelios Klinikum Emil von Behring · DEKliniken Essen-Mitte · DEMedical University of Graz · ATRuhrlandklinik · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMalignant pleural mesothelioma (MPM) is a rare malignant tumor associated with asbestos exposure, with infaust prognosis and overall survival below 20 months in treated patients. Platinum is still the backbone of the chemotherapy protocols, and the reasons for the rather poor efficacy of platinum compounds in MPM remain largely unknown. Therefore, we aimed to analyze differences in key signaling pathways and biological mechanisms in therapy-naïve samples and samples after chemotherapy in order to evaluate the effect of platinum-based chemotherapy.

methodsThe study cohort comprised 24 MPM tumor specimens, 12 from therapy-naïve and 12 from patients after platinum-based therapy. Tumor samples were screened using the NanoString nCounter platform for digital gene expression analysis with an appurtenant custom-designed panel comprising a total of 366 mRNAs covering the most important tumor signaling pathways. Significant pathway associations were identified by gene set enrichment analysis using the WEB-based GEne SeT AnaLysis Toolkit (WebGestalt).

resultsWe have found reduced activity of TNF (normalized enrichment score: 2.03), IL-17 (normalized enrichment score: 1.93), MAPK (normalized enrichment score: 1.51), and relaxin signaling pathways (normalized enrichment score: 1.42) in the samples obtained after platinum-based therapy. In contrast, AMPK (normalized enrichment score: -1.58), mTOR (normalized enrichment score: -1.50), Wnt (normalized enrichment score: -1.38), and longevity regulating pathway (normalized enrichment score: -1.31) showed significantly elevated expression in the same samples.

conclusionsWe could identify deregulated signaling pathways due to a directed cellular response to platinum-induced cell stress. Our results are paving the ground for a better understanding of cellular responses and escape mechanisms, carrying a high potential for improved clinical management of patients with MPM.

Indexed as

Gene Set Enrichment AnalysisMalignant pleural mesothelioma (MPM)platinum resistance, gene expression

Identifiers

PMID34430345
PMCPMC8350085
OpenAlexW3180654723

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.